This study is for women with recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer that is resistant to platinum-based chemotherapy and have had prior therapy with bevacizumab.The purpose of the study is to see if the combinations of durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) and cediranib, or olaparib and cediranib keep patients disease free longer than the usual approach.
This study is for subjects that have platinum-resistant recurrent ovarian cancer. The study is testing an "investigational" study drug called AVB-S6-500. The primary purpose of this study is to evaluate the safety and efficacy of AVB-S6-500 combined with PAC in subjects with platinum-resistant, recurrent ovarian cancer. The subjects may remain in the study for up to 24-months. The subjects will be seen at MUSC every 1 to 2 weeks while receiving study treatment and given the study drug by infusion (IV).
This study is for women with endometrial cancer. The purpose is to find out if adding a new immunotherapy drug to the usual combination of chemotherapy drugs can lower the chance of your endometrial cancer growing or spreading.
This study is for adult women who have advanced or recurrent endometrial (uterine) cancer. The purpose is to find out if the drug combination of paclitaxel, carboplatin and metformin works better than paclitaxel and carboplatin alone in treating uterine cancer.